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tagonists of AT1 and AT2 receptors, failed to modify PAI-1Angiotensin IV stimulates plasminogen activator inhibitor-1
mRNA expression as induced by Ang II.expression in proximal tubular epithelial cells.
Conclusions. Our results demonstrate that Ang II stimulatesBackground. Angiotensin II (Ang II) has been shown to be
PAI-1 mRNA expression and the production of its protein inimplicated in the development of renal fibrosis in several forms
human proximal tubular cells. This is mainly—if not exclu-of chronic glomerulonephritides, but the precise mechanisms
sively—due to Ang IV, which acts on a receptor that is differentof its effects remain unclear. It has recently been reported
than AT1 or AT2. Therefore, it can be hypothesized that thethat Ang II stimulates the expression of plasminogen activator
induction of PAI-1 by Ang IV may be implicated in the patho-inhibitor-1 (PAI-1) in several cell lines. PAI-1 is a major physio-
genesis of renal interstitial fibrosis in several forms of chroniclogical inhibitor of the plasminogen activator/plasmin system,
glomerulonephritides.a key regulator of fibrinolysis and extracellular matrix (ECM)
turnover. PAI-1 induction by Ang II in endothelial cells seems
to be mediated by Ang IV via a receptor that is different from
Ang II type 1 and 2 receptors (AT1 and AT2). Besides its pivotal role in the regulation of extracellu-
Methods. In this study, we sought to evaluate the effects
lar volume and systemic blood pressure, the renin-angio-of Ang IV on PAI-1 gene and protein expression in a well-
tensin system (RAS) also functions at the intracrine,characterized and immortalized human proximal tubular cell
line (HK2) by Northern blot and enzyme-linked immunosor- autocrine, and paracrine levels [1–8]. Its components
bent assay. [angiotensinogen, renin, angiotensin converting enzyme
Results. Ang IV stimulated PAI-1 mRNA expression, (ACE), and aminopeptidases (APs)] have been found
whereas it did not induce a significant increase in tritiated
in many tissues, and there is overwhelming evidence ofthymidine uptake after 24 hours of incubation. This effect was
a local angiotensin II (Ang II) biosynthesis [revieweddose and time dependent. Ang IV (10 nm) induced a 7.8 6
in 9]. The kidney and the blood vessels represent two3.3-fold increase in PAI-1 mRNA expression. The PAI-1 anti-
gen level was significantly higher in conditioned media and the examples of target tissues as well as sites of production
ECM of cells treated with Ang II and Ang IV than in control and degradation of Ang II [10, 11]. This is particularly
cells (both P , 0.02). Although Ang II induced a 4.2 6 2.1- evident in the proximal tubule, where the Ang II concen-fold increase in PAI-1 mRNA expression, its effect underwent
tration is 1000 times higher than in plasma [12, 13].a dose-dependent reduction when amastatin, a potent inhibitor
Several studies have clearly shown that intrarenalof the endopeptidases that catalyzes the conversion of Ang II
to Ang IV, was added. In contrast, amastatin was not able to RAS plays an important role not only in the regulation
prevent the expression of PAI-1 mRNA induced by Ang IV. of renal hemodynamics but also in the pathogenesis of
Finally, pretreatment of HK2 cells with losartan and N-Nicoti- renal fibrosis [1, 2, 14–16]. Recent data suggest that the
noyl-Tyr-N3-(Na-CBZ-Arg)-Lys-His-Pro-Ile, the specific an-
Ang II blockade may also act through pressure-indepen-
dent mechanisms to induce the repair of tissue injury.
Indeed, it has been demonstrated that ACE inhibitorsKey words: interstitial fibrosis, human proximal tubular cells, PAI-1,
angiotensin IV. and Ang II receptor antagonists attenuate progressive
renal fibrosis in several disease models, and slow diseaseReceived for publication May 8, 1998
progression in several forms of human glomerulone-and in revised form January 29, 1999
Accepted for publication March 9, 1999 phritides [14, 17–23]. The precise mechanisms by which
Ang II induces renal fibrosis are still unclear. 1999 by the International Society of Nephrology
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Until recently, Ang II and its metabolite Ang III were ferrin, and sodium selenite were obtained from Sigma
Cell Colture (Milan, Italy). Trypsin, penicillin, and strep-considered to be the only bioactive agents [24]. Shorter
fragments, such as Ang IV, were denied any physiologi- tomycin were obtained from Mascia Brunelli (Milan,
Italy). Epidermal growth factor was obtained from Calbi-cal interest, as they lacked the effects of Ang II and Ang
III [24]. However, new findings indicate that the actions ochem (La Jolla, CA, USA). PGE1, hydrocortisone, and
T3 were purchased from Sigma Chemical Co. (Milan,of the RAS are mediated, in addition to Ang II and
Ang III, by a variety of angiotensin peptides binding to Italy). Ang II and Ang IV were obtained from Peninsula
Laboratories (Belmont, CA, USA). Amastatin was ob-multiple receptors [25–30]. Locally synthesized Ang II
therefore has the potential to directly activate its specific tained from Sigma Chemical Co. (Milan, Italy). Losartan
was kindly donated by DuPont Merck Pharmaceuticalneighboring receptors, but it is also hydrolyzed by several
cell-associated brush border enzymes into shorter frag- Company (Wilmington, DE, USA). [32P]dCTP and
[methyl-3H]-thymidine were purchased from Amershamments, such as Ang IV, which may activate their own
receptors. (Little Chalfont, Buckinghamshire, UK). All other
chemicals were reagent grade.In endothelial cells, it has been reported that the induc-
tion of plasminogen activator inhibitor-1 (PAI-1) expres-
Cell culturesion by Ang II is mediated by Ang IV via a receptor
that is different than AT1 and AT2 [31]. PAI-1 is a major HK2 cells, an immortalized proximal tubular epithelial
cell (PTEC) line from normal adult human kidney [37],physiological inhibitor of tissue-type plasminogen activa-
tor (t-PA) and urokinase-type plasminogen activator were obtained from ATCC (Rockville, MD, USA). Cells
were grown to confluence in DMEM/F12 medium sup-(u-PA) and, therefore, plays an important role in the
regulation of the PA/plasmin system [32]. This system plemented with 5% heat-inactivated FBS, 100 U/ml
penicillin, 100 mg/ml streptomycin, 2 mm l-glutamine, 5is not only a key regulator of fibrinolysis, but also partici-
pates in extracellular matrix (ECM) degradation. In- mg/ml insulin, 5 mg/ml transferrin, and 5 ng/ml sodium
selenite, 5 pg/ml T3, 5 ng/ml hydrocortisone, 5 pg/mldeed, PAI-1 prevents the transformation of the metallo-
proteinases, which are potent ECM degradation enzymes, PGE1, and 10 ng/ml epidermal growth factor. For pas-
sage, confluent cells were washed with phosphate-buf-from the latent to the active form by blocking the activa-
tion of plasminogen in plasmin [32]. fered saline (PBS), removed with trypsin 0.05%/ethyl-
enediaminetetraacetic acid (EDTA) 0.2% in PBS, andTubulointerstitial fibrosis is the net result of increased
ECM deposition and/or diminished ECM degradation. plated in DMEM/F12. Following these culture condi-
tions, the cells retained a phenotype indicative of well-Renal tubular cells, previously considered to be passive
targets of the inflammatory process, seem to be impli- differentiated PTECs as previously demonstrated [37,
38] and as confirmed by our studies. Cells were posi-cated in the pathogenesis of renal tubulointerstitial fi-
brosis [reviewed in 33]. Indeed, in response to different tive for cytokeratin, antiadenosine deaminase-binding
protein antibody (CD26), alkaline phosphatase, andstimuli, they are able to produce an array of inflamma-
tory and profibrogenic molecules. Moreover, they ex- CHIP28 (a proximal tubule water channel), and were
negative for Tamm-Horsfall protein (data not shown).press angiotensinogen, renin, ACE, and AP and possess
specific receptors for Ang II and its metabolites [9, 26]. The cells were washed with fresh serum-free DMEM/
F12 medium and starved in serum-free medium for 24Interestingly, an increase of ACE and PAI-1 has been
reported in pathological conditions involving the renal hours, and then the indicated concentrations of Ang II
or Ang IV were added in the presence or absence oftubule [34–36].
Therefore, we evaluated the effects of Ang II and the AT1 receptor antagonist (DuP 753/MK 954, losar-
tan), AT2 receptor antagonist [N-Nicotinoyl-Tyr-N3-Ang IV on the expression of PAI-1 mRNA in a well-
characterized and immortalized human proximal tubular (Na-CBZ-Arg)-Lys-His-Pro-Ile], or Amastatin. Primary
PTECs were obtained according to the method describedcell line [37]. Moreover, we addressed the hypothesis
that PAI-1 mRNA expression by human proximal tubu- by Detrisac et al from apparently normal portions of
nephrectomy specimens [39]. PTECs were cultured fol-lar cell may be mediated by a specific receptor for Ang
IV, and we speculated on the role played by the Ang lowing the protocol used for HK2 cells.
II metabolites in the pathogenesis of tubulointerstitial
DNA synthesisfibrosis.
DNA synthesis was measured as the amount of
[methyl-3H]-thymidine incorporated into trichloroacetic
METHODS
(TCA)-precipitable material. Cells were plated in 24-
Reagents well dishes at a density of 4 3 104 per well, were grown
to confluence, and were made quiescent by placing themDulbecco’s modified Eagle’s medium (DMEM)/F12,
fetal bovine serum (FBS), l-glutamine, insulin, trans- in serum-free medium for 24 hours. Then cells were
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Fig. 2. Effect of different angiotensin (Ang) II (h) and Ang IV (j)
concentrations on plasminogen activator inhibitor-1 (PAI-1) expression
by proximal tubular epithelial cells (PTECs). Confluent cultures of
PTEC were washed, serum starved, and then incubated with vehicle,
Ang II, or Ang IV for three hours at the indicated concentrations. The
expression of PAI-1 mRNA after exposure to Ang II and Ang IV was
determined by densitometry and was normalized using the 28S band.
Data represent means 6 sd (N 5 3, each point in triplicate).
cosyl, and 0.1 mm 2-b-mercaptoethanol. Total RNA was
isolated by the single-step method, using phenol andFig. 1. (A) Effect of angiotensin (Ang) II (j) and Ang IV (h) on
chloroform/isoamylalcohol [40].proximal tubular epithelial cell (PTEC) DNA synthesis. Tritiated thymi-
dine incorporation is expressed as count per min/well. (B) Effect of Plasminogen activator inhibitor-1, PAI-2, u-PA, t-PA,
Ang II and IV on PTEC proliferation. Ang II and IV did not cause a and transforming growth factor-b1 (TGF-b1) gene ex-
significant and dose-dependent increase in DNA synthesis, as well as
pression was studied by Northern blotting as previouslyin cell number. Data represent means 6 sd (N 5 3, each point in
quadruplicate). described [41]. The cDNA probes used for Northern
blotting analysis were a 790 bp fragment encoding the
human PAI-2 cDNA, a 600 bp fragment of the human
u-PA cDNA (kindly provided by Dr. S. Moll and Dr.
incubated with Ang II and Ang IV at the indicated con- D. Belin, Laboratoire de Nefrologie, Geneve, France),
centrations for 24 hours at 378C. At the end of the incuba- a 1200 bp fragment of the human PAI-1 cDNA, a 770
tion period, cells were pulsed for four hours with 1.0 bp fragment of the human t-PA cDNA (kindly provided
mCi/ml of 3H-thymidine. The medium was then removed, by Dr. R. Lorenzet, M. Negri Sud, S. Maria Imbaro;
and cells were washed twice in ice-cold 5% TCA and originally from Dr. D. Loskutoff, Scripps Clinic, La Jolla,
incubated in 5% TCA for five minutes. Cells were solubi- CA, USA), and a 2140 bp fragment encoding the human
lized by adding 0.75 ml of 0.25 N NaOH in 0.1% sodium TGF-b1 cDNA (kindly provided by Dr. S. Milani, De-
dodecyl sulfate (SDS). One-half milliliter aliquots were partment of Gastroenterology, University of Florence,
then neutralized and counted in scintillation fluid by Florence, Italy). Briefly, electrophoresis of 20 mg total
using a b counter. RNA from each experimental condition was carried out
in 1% agarose gel with 2.2 m formaldehyde. The gel was
RNA isolation and Northern blot analysis stained with ethidium bromide to evaluate the 28S and
Proximal tubular epithelial cells were grown to con- 18S ribosomal bands and was transferred overnight to a
fluence, rested for 24 hours in serum-free medium, and nylon membrane (Schleicher & Schuell, Dassel, Ger-
then incubated with Ang II or Ang IV with or without many). The membrane was prehybridized at 428C for
the antagonists at the indicated concentrations for 0, 3, two hours in 50% formamide, 0.5% SDS, 5 3 standard
6, 12, and 24 hours at 378C. At the end of the incubation saline citrate (SSC), and 0.1 mg/ml salmon sperm DNA.
period, cells were lyzed with 4 m guanidium isothiocya- The cDNA probes were labeled by random priming
using a commercially available kit (Amersham) andnate containing 25 mm sodium citrate, pH 7.0, 0.5% sar-
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Fig. 3. (A and B) Time course of Ang II and Ang IV-induced plasmino-
gen activator inhibitor-1 (PAI-1) expression by proximal tubular epithe-
lial cells (PTECs). Confluent cultures of PTECs were washed, serum
starved, and incubated with vehicle, Ang II (10 nm), and Ang IV (10
nm) for the indicated time periods. The expression of the PAI-1 mRNA
is demonstrated in the upper panel. To control for variation in gel
loading, the relative amounts of RNA in each lane were visualized by
staining with ethidium bromide. (C) Time course of Ang II (h) and
Ang IV (r) induced increase of PAI-1 expression by PTECs. The
expression of PAI-1 mRNA after exposure to Ang II and Ang IV was
determined by densitometry and normalized using the 28S band.
[32P]dCTP (specific activity, 3000 Ci/mmol). The probe then incubated with Ang II or Ang IV at the indicated
concentrations for 24 hours at 378C. At the end of incuba-(106 cpm/ml) was added to 10 ml of prehybridization
solution, and the blots were hybridized for 16 hours at tion, conditioned media were collected, centrifuged, and
stored at 2808C until assayed. The cell monolayer was428C. The membranes were then washed once in 2 3
SSC, 0.1% SDS at room temperature for five minutes, washed twice with culture medium and then treated with
0.5 ml of 0.02 m Tris, 0.15 m NaCl, pH 7.4, containingonce in the same buffer at 558C for 30 minutes, and in
1 3 SSC, 0.1% SDS at 558C for an additional 30 minutes. 0.5% Triton X-100. After incubation for 45 minutes at
room temperature on a rotating plate, the resulting cellAfter drying, membranes were exposed to a Kodak
X-OMAT film with intensifying screens at –708C. extract was removed by aspiration, and the Triton X-
100–insoluble ECM was washed twice with Tris buffer.
Measurement of plasminogen activator inhibitor-1 in ECM-associated PAI-1 was then brought into solution
conditioned medium and extracellular matrix by the addition of 0.3 ml of 1 mg/ml of t-PA and incubated
for two hours at 378C. This treatment resulted in moreProximal tubular epithelial cells were grown to con-
fluence, rested for 24 hours in serum-free medium, and than an 80% release of PAI-1 as PAI-1/t-PA complex,
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as previously reported [42]. PAI-1 antigen was measured
by an enzyme-linked immunosorbent assay (ELISA)
method (Biopool, Umea, Sweden) and expressed as ng
per 100,000 cells (conditioned media) or ng/ml (ECM
associated).
Statistical analysis
Results are presented as mean 6 sd. Statistical signifi-
cance was determined using one-way analysis of variance
and the unpaired t-test. A P value of less than 0.05 was
considered statistically significant. Triplicate wells were
analyzed for each experiment, and each experiment was
performed independently at least three times.
Fig. 4. Effect of the aminopeptidase inhibitor amastatin on Ang II-
RESULTS induced PAI-1 expression in proximal tubular epithelial cells (PTECs).
Confluent cultures of PTECs were washed, serum starved, and incu-Effect of Ang II and IV on PTEC proliferation
bated with vehicle or Ang II (10 nm) with or without increasing concen-
tration of amastatin (0 to 1000 nm). Data represent the means 6 sdAs previously reported [1, 2], the treatment of PTEC
(N 5 3, each point in triplicate).with Ang II did not cause an increase of either [3H]-
thymidine incorporation or cell number (P 5 NS; Fig. 1).
Similar effects were observed with Ang IV (P 5 NS;
Fig. 1). Lys-His-Pro-Ile, specific antagonists of AT1 and AT2
receptors, did not show any variation of PAI-1 mRNAEffect of Ang II and IV on PAI-1 mRNA expression
expression when compared with cells treated with Ang
HK2 cells were exposed to Ang II or Ang IV for three II alone (Fig. 6).
hours over the concentration range of 0 to 20 nm. At the
end of incubation, cells were lyzed. RNA was extracted, Effect of angiotensin II and IV on u-PA, t-PA, and
and PAI-1 gene expression was evaluated by Northern PAI-2 expression
blotting. In basal conditions, PAI-1 mRNA was ex-
Angiotensin II and Ang IV did not induce any varia-pressed at low but detectable levels (Fig. 2). Ang II and
tion in u-PA mRNA expression (Fig. 7), whereas t-PAAng IV induced a dose-dependent increase of PAI-1
and PAI-2 mRNA expression were undetectable (dataexpression (Fig. 2), which reached its plateau at a concen-
not shown).tration of 10 nm of either agent. Exposure of the cells
to 10 nm Ang II or Ang IV resulted in a 4.2 6 2.1-fold Effects of Ang II and IV on TGF-b expression
and 7.8 6 3.3-fold increase in the expression of PAI-1,
It has been previously demonstrated that Ang II isrespectively (Fig. 2). A time-dependent increase of Ang
able to induce a profibrotic factor, that is, TGF-b, inII- and Ang IV-induced PAI-1 expression was also dem-
PETCs via the AT1 receptor. Thus, to demonstrate thatonstrated, which seemingly peaked at three hours (Fig.
HK2 cells were responsive to Ang II and that the lack3 A, C). The same results were obtained with primary
of a direct effect of Ang II on PAI-1 expression was notPTEC (data not shown).
due to the absence of AT1 receptors, the same total
Effects of amastatin, AT1 and AT2 receptor RNA shown in Figure 3 was hybridized with TGF-b
antagonists on the response to Ang II and IV cDNA. As shown in Figure 7, although Ang II induced
a 2.8 6 0.6-fold increase of TGF-b1 mRNA expression,Amastatin is a potent inhibitor of aminopeptidases P
with a maximal effect at 12 hours, Ang IV was devoid ofand APN, which prevent the conversion of Ang II to
any effect on TGF-b mRNA expression. Finally, losartansmaller fragments, including Ang IV [9]. Figure 4 shows
was able to prevent TGF-b mRNA expression inducedthat amastatin strongly reduced Ang II-induced PAI-1
by Ang II (Fig. 8).mRNA expression in a dose-dependent manner, and at
a concentration of 1 mm, it completely abrogated the
Effects of Ang II and IV on PAI-1 protein synthesiseffect of 10 nm Ang II. In contrast, amastatin was unable
To demonstrate that the rise in PAI-1 mRNA in PTECto prevent the expression of PAI-1 mRNA induced by
culture was accompanied by the synthesis of PAI-1 pro-10 nm Ang IV (Fig. 5). Furthermore, Ang IV-dependent
tein, PAI-1 antigen was measured by a commerciallyinduction of PAI-1 mRNA was supported by an experi-
available ELISA assay kit. PAI-1 antigen was signifi-ment in which cells stimulated by Ang II, pretreated
with losartan and N-Nicotinoyl-Tyr-n3-(na-CBZ-Arg)- cantly increased in both Ang II- and Ang IV-stimulated
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Fig. 5. Effect of the aminopeptidase inhibitor
amastatin on angiotensin (Ang) II/IV-induced
plasminogen activator inhibitor-1 (PAI-1) ex-
pression in proximal tubular epithelial cells
(PTECs). Confluent cultures of PTECs were
washed, serum starved, and incubated with
vehicle (A and D), Ang II (10 nm; B), or Ang
IV (10 nm; E). In (C and F ), cells were incu-
bated with Ang II and Ang IV plus amastatin
(1000 nm), respectively.
PTECs (basal, 9.3 6 0.6 ng/100,000 cells; Ang II, 12.3 6 minogen activators even in the presence of adherent cells
[42].1.9 ng/100,000 cells; and Ang IV, 13.9 6 1.7 ng/100,000
cells, P , 0.02). Because this difference was less pro-
nounced than that observed at mRNA level, we deter- DISCUSSION
mined the amount of PAI-1 associated with the ECM
In this study, for the first time to our knowledge, we
and found that in both Ang II- and Ang IV-treated cells, demonstrated that the exapeptide Ang IV induces PAI-1
the amount of ECM-associated inhibitor was higher than mRNA expression in human PTECs in a time- and dose-
in control cells (basal, 35 6 0.6 ng/ml; Ang II, 51.9 6 dependent manner. Moreover, our results suggest that
8.5 ng/ml; and Ang IV, 40.8 6 2.16 ng/ml, P , 0.02). It PAI-1 mRNA expression induced by Ang II in PTECs
is conceivable that treatment with Ang II and Ang IV is mediated by Ang IV, supporting the data reported by
enhances PAI-1 production as well as PAI-1 accumula- Kerins, Hao, and Vaughan in endothelial cells [31]. This
tion within the ECM. It should be noted that ECM- conclusion was drawn from the demonstration that the
use of amastatin, a potent inhibitor of APs, abrogatedassociated PAI-1 is active and accessible to soluble plas-
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Fig. 6. (A) Effect of losartan on angiotensin
(Ang) II-induced plasminogen activator in-
hibitor-1 (PAI-1) expression by proximal tu-
bular epithelial cells (PTECs). Confluent cul-
tures of PTECs were washed, serum starved,
and incubated with vehicle (lane 1) or Ang II
(10 nm; lane 2). In lanes 3 and 4, cells were
preincubated with an AT1 receptor antagonist
(1 mm; losartan; lane 3) or with amastatin (1
mm; lane 4). The expression of PAI-1 mRNA
after exposure to Ang II was normalized using
the 28S band. (B) Effect of N-Nicotinoyl-Tyr-
N3-(Na-CBZ-Arg)-Lys-His-Pro-Ile on Ang
II-induced PAI-1 expression by PTECs. Con-
fluent cultures of PTECs were washed, serum
starved, and incubated with vehicle (lane 1)
or Ang II (10 nm; lane 2). In lanes 3 and 4,
cells were preincubated with an AT2 receptor
antagonist [1 mm; N-Nicotinoyl-Tyr-N3-(Na-
CBZ-Arg)-Lys-His-Pro-Ile; lane 3] or with
amastatin (1 mm; lane 4). Expression of PAI-1
mRNA after exposure to Ang II was normal-
ized using the 28S band.
Ang II into Ang III and Ang IV [9]. At least two APs,
A and N, are involved in this process. APA, also known
as angiotensinase, converts Ang II into Ang III, whereas
APN converts Ang III into the hexapeptide Ang IV [9].
Both enzymes, APA and APN, have been found on the
brush border of the proximal tubule [43, 44]. Amastatin
is a potent inhibitor of both aminopeptidases with an
IC50 of 0.2 mm [45]. Moreover, the kidney expresses a
specific receptor for Ang IV, named AT4. Harding et al
have shown that it is preferentially concentrated in the
outer stripe of medulla [46]. Finally, it has been reported
that PTECs may express angiotensinogen, renin, and
ACE [10–13, 47].
It is conceivable that in the setting of an inflammatory
process, such as tubulointerstitial nephritis, angioten-
Fig. 7. Effect of angiotensin (Ang) II and Ang IV on u-PA and trans- sinogen gene transcription may be activated by proin-
forming growth factor-b (TGF-b) expression by proximal tubular epi-
flammatory cytokines, that is, interleukin-1b and tumorthelial cells (PTECs). Confluent cultures of PTECs were washed, serum
starved and incubated with vehicle, Ang II (10 nm), or Ang IV (10 nm) necrosis factor-a, produced by macrophages or intrinsic
for 0 to 24 hours. No differences were observed in Ang II and Ang IV renal cells [33]. Indeed, both of these cytokines induce
induced u-PA expression at any time point. Ang II induced an increase
two transcription factors, nuclear factor-kB (NF-kB) andof TGF-b mRNA expression, with a maximal effect at 12 hours. Ang
IV was devoid of any effect on TGF-b mRNA expression. Expression a member of the CCAT/enhancer binding protein family,
of u-PA and TGF-b1 mRNA after exposure to Ang II and Ang IV both of which are able to bind and to induce a singlewas normalized to GAPDH expression.
regulatory site in the angiotensinogen promoter [48].
Moreover, Ang II per se may activate NF-kB. This was
indirectly demonstrated by Morrissey and Klahr, who
were able to obtain a significant reduction of NF-kBPAI-1 mRNA expression induced by Ang II but not by
activity rat kidneys with unilateral obstruction by usingAng IV.
Aminopeptidases (APs) are enzymes that degrade with enalapril [49]. Thus, it can be hypothesized that at
Gesualdo et al: Ang IV stimulates PAI-1 expression468
PAI-1, the specific angiotensin receptor subtype mediat-
ing this response was not defined [15, 34, 51, 60–63].
Kagami et al demonstrated that the addition of Ang II
to mesangial cells in culture increased the expression of
PAI-1 mRNA [15]. No aminopeptidase inhibitors were
used in this study. However, they excluded that the in-
creased expression of PAI-1 mRNA induced by Ang II
was mediated by TGF-b. Indeed, coincubation of mesan-
gial cells with Ang II and a neutralizing antibody to
TGFb1 did not alter the PAI-1 mRNA expression. In
our study, we demonstrated that Ang II is capable of
stimulating the expression of PAI-1 and that this effect
is Ang IV mediated. Moreover, Ang II was able to induce
TGF-b expression directly, whereas Ang IV failed to
evoke such an effect. Our findings appear particularly
interesting because they may support the hypothesis that
the activation of RAS system induces fibrosis by follow-
Fig. 8. Effect of losartan on angiotensin (Ang) II-induced TGF-b ex-
ing two separate pathways: through TGF-b that is in-pression by proximal tubular epithelial cells (PTECs). Confluent cul-
tures of PTECs were washed, serum starved, and incubated with vehicle duced by Ang II, and through PAI-1 that is mediated
(lane 1) or Ang II (10 nm; lanes 2 through 5). In lanes 3 through 5, by Ang IV. This hypothesis may have important clinicalcells were preincubated with amastatin (1 mm; lane 3), with an AT2
implications. Specific AT1 or AT2 receptor antagonists,receptor antagonist [1 mm; N-Nicotinoyl-Tyr-N3-(Na-CBZ-Arg)-Lys-
His-Pro-Ile; lane 4] and with an AT1 receptor antagonist (1 mm; losartan; although preventing NF-kB induction by Ang II [49],
lane 5). Expression of TGF-b mRNA after exposure to Ang II was
may lack any favorable effect on the fibrinolytic system.normalized using the 28S band.
On the other hand, captopril has been shown to decrease
PAI-1 activity in patients with recent uncomplicated
myocardial infarction [64–67]. Obviously, clinical pro-
the tubular level the activation of the intrinsic RAS sys- spective studies comparing these two classes of drugs
tem by inflammatory stimuli may create a positive loop interfering with the RAS system at different sites are
perpetuating the renal damage. The finding that tubular now warranted to support the previously mentioned hy-
cells express APA and APN is of significant interest [43, pothesis.
44]. Therefore, in an inflammatory process, the presence In conclusion, our study demonstrates that (a) Ang IV
of higher amounts of intratubular Ang II may be accom- is the form of angiotensin that stimulates PAI-1 mRNA
panied by an increase of its metabolites, including Ang expression in human proximal tubular cells. (b) The ef-
IV. This Ang II metabolite inducing PAI-1 may in turn
fects of Ang IV seem to be mediated by a receptor that
be responsible for the increased accumulation of ECM,
is specific for Ang IV. (c) Ang IV, inducing PAI-1 mRNAby inhibiting its degradation [32]. The proinflammatory
expression, may be implicated in the pathogenesis ofand profibrotic role of the intrinsic RAS system is indi-
renal interstitial fibrosis.rectly supported by both animal and human studies [34,
50–58]. In different models of tubulointerstitial injury,
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